Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-24
2007-04-24
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
10390426
ABSTRACT:
In one aspect, the present invention provides a method of modulating an Edg-3 receptor mediated biological activity in a cell. A cell expressing the Edg-3 receptor is contacted with a modulator of the Edg-3 receptor sufficient to modulate the Edg-3 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-3 receptor mediated biological activity in a subject. A therapeutically effective amount of a modulator of the Edg-3 receptor is administered to the subject. In yet another aspect, compounds and composition useful for modulation of the Edg-3 receptor are presented.
REFERENCES:
patent: 3178348 (1965-04-01), Bickerton
patent: 5478832 (1995-12-01), Inoue et al.
patent: 5622967 (1997-04-01), Dolle et al.
patent: 5872130 (1999-02-01), Fujikawa et al.
patent: 6077851 (2000-06-01), Bjork et al.
Harrison's Principles of Internal Medicine, vol. 1, 13th ed., Isselbacher et al. (eds.), published 1994 by McGraw-Hill, Inc., pp. 1108-1116.
Cecil Text Book of Medicine, 21st ed., vol. 1, pp. 258-273 (2000).
K. Bandoh et al., “Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species Structure-activity relationship of cloned LPA receptors,”Federation of European Biochemical Societies, 478 (2000) 159-165.
D. Im et al., “Molecular Cloning and Characterization of a Lysophosphatidic Acid Receptor, Edg-7, Expressed in Prostate,”The American Society for Pharmacology and Experimental Therapeutics, 57:753-759 (2000).
Annals of the New York Academy of Sciences, vol. 905:1-357, Lysophospholipids and Eicosanoids in Biology and Pathophysiology, Edited by Edward J. Goetzl and Kevin R. Lynch, 2000.
M. Gräler et al., “EDG6, a Novel G-Protein-Coupled Receptor Related to Receptors for Bioactive Lysophospholipids, Is Specifically Expressed in Lymphoid Tissue,”Genomics53, 164-169 (1998), Article No. GE985491.
Gluchowski Charles
Shankar Geetha
Solow-Cordero David
Spencer Juliet V.
Henley III Raymond J.
Maniv Energy Capital
Morgan & Lewis & Bockius, LLP
LandOfFree
Methods of treating conditions associated with an Edg-3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating conditions associated with an Edg-3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating conditions associated with an Edg-3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3752615